uniQure (NASDAQ:QURE) Given “Outperform” Rating at Raymond James

Raymond James reiterated their outperform rating on shares of uniQure (NASDAQ:QURE) in a research report sent to investors on Thursday, Marketbeat.com reports. The brokerage currently has a $20.00 price target on the biotechnology company’s stock.

Several other research firms have also recently weighed in on QURE. StockNews.com upgraded uniQure to a sell rating in a research note on Monday, August 5th. The Goldman Sachs Group upped their target price on uniQure from $6.00 to $10.00 and gave the stock a neutral rating in a research note on Friday, August 2nd. Cantor Fitzgerald reiterated an overweight rating and issued a $28.00 price target on shares of uniQure in a research note on Friday, September 20th. Finally, HC Wainwright reiterated a buy rating and issued a $25.00 price target on shares of uniQure in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, uniQure currently has an average rating of Hold and an average target price of $19.50.

uniQure Price Performance

Shares of QURE stock traded down $0.14 during trading on Thursday, hitting $5.28. The company had a trading volume of 37,143 shares, compared to its average volume of 1,474,792. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36. The firm has a market capitalization of $257.14 million, a P/E ratio of -0.91 and a beta of 0.95. The stock’s 50-day moving average price is $5.93 and its 200 day moving average price is $5.63. uniQure has a one year low of $3.73 and a one year high of $11.35.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.08. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $3.47 million. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. Equities analysts expect that uniQure will post -4.04 EPS for the current fiscal year.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 58.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 3,664 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the period. Total Clarity Wealth Management Inc. acquired a new stake in uniQure during the 2nd quarter worth about $74,000. SG Americas Securities LLC acquired a new stake in uniQure during the 2nd quarter worth about $79,000. Finally, Cubist Systematic Strategies LLC grew its holdings in uniQure by 130.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 14,454 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.